Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 18,197 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 18,197 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $34.03, for a total transaction of $619,243.91. Following the completion of the sale, the chief financial officer directly owned 284,321 shares in the company, valued at approximately $9,675,443.63. This trade represents a 6.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, May 18th, Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.64, for a total transaction of $187,938.00.
• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.90, for a total value of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.83, for a total value of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total value of $79,420.50.

Hims & Hers Health Price Performance

HIMS opened at $33.00 on Wednesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The stock has a market capitalization of $7.64 billion, a PE ratio of -366.67, a price-to-earnings-growth ratio of 47.94 and a beta of 2.37. The stock’s 50 day moving average price is $27.29 and its 200-day moving average price is $26.51. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.20 EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.05 EPS for the current year.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers is expanding its GLP-1 weight-loss offering through a partnership with Novo Nordisk, which could broaden access to popular drugs like Wegovy and Ozempic and support revenue growth. Hims & Hers Health (HIMS) Expands GLP 1 Offerings With Novo Nordisk Deal And Eucalyptus Buy
• Positive Sentiment: The company also announced a new chief medical officer, Dr. Anant Vinjamoori, which may be viewed as a strengthening of its leadership team. Telehealth platform names Dr. Anant Vinjamoori as Hims CMO
• Neutral Sentiment: Analyst commentary and market articles highlighted Hims & Hers as one of several stocks that may deserve another look, but also noted that bearish price targets signal ongoing skepticism. 2 Unpopular Stocks That Deserve a Second Chance and 1 We Question
• Negative Sentiment: Insiders continued to trim holdings, with CFO Oluyemi Okupe and insider Patrick Harrison Carroll both selling shares under pre-arranged 10b5-1 plans, which can still weigh on investor sentiment. CFO insider sale filing
• Negative Sentiment: The stock also recently fell more than the broader market, reinforcing concerns that some traders may be taking profits after the recent rally. Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Analyst Upgrades and Downgrades

Several analysts have commented on HIMS shares. Canaccord Genuity Group set a $32.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 12th. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a research report on Tuesday, May 12th. UBS Group set a $23.00 target price on Hims & Hers Health in a research note on Friday, May 22nd. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Evercore set a $24.00 price objective on Hims & Hers Health in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $29.37.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently made changes to their positions in HIMS. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health during the 4th quarter valued at approximately $28,000. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health in the third quarter worth $28,000. Bogart Wealth LLC grew its stake in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health during the first quarter valued at $30,000. Finally, Greenline Wealth Management LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at $36,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.